Allergan & AbbVie v. MSN Laboratories: Eluxadoline ANDA Infringement Resolved by Consent Injunction
AbbVie, Allergan, and Eden Biodesign filed suit in Delaware against MSN Laboratories over ANDA No. 213576 for generic eluxadoline (Viberzi) tablets. The case resolved in 306 days via a stipulated order in which MSN conceded infringement and accepted a permanent injunction barring US commercialisation of the generic product for the life of the asserted patents.
Consent injunction blocks MSN’s generic eluxadoline — Viberzi IP wall holds
On 23 October 2024, Allergan Holdings Unlimited Co., AbbVie US LLC, AbbVie, Inc., and Eden Biodesign, LLC filed a Hatch-Waxman infringement action in the District of Delaware (Case No. 1:24-cv-01187) against MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. The suit targeted MSN’s ANDA No. 213576, which sought FDA approval to market generic eluxadoline oral tablets in 75 mg and 100 mg strengths — the bioequivalent of Allergan’s branded Viberzi® product used to treat irritable bowel syndrome with diarrhoea.
The action concluded on 25 August 2025 via a court-entered stipulation and order. MSN conceded that the filing of its ANDA constituted an act of infringement of the ‘527 Patent and US12097187B2 (the ‘187 Patent) under 35 U.S.C. § 271(e)(2)(A). The court entered a permanent injunction prohibiting MSN from manufacturing, using, selling, offering to sell, or importing the ANDA-described generic eluxadoline products in the United States for the life of both asserted patents, including any patent-term extensions or paediatric exclusivities, absent a licence from plaintiffs.
At 306 days, the case resolved notably faster than the typical Hatch-Waxman ANDA trial timeline, suggesting MSN’s non-validity challenge position made protracted litigation commercially unattractive. The without-prejudice dismissal of remaining claims preserves both parties’ rights regarding the same patents and different products, leaving open a potential future ANDA path for MSN. The public record does not disclose any licensing agreement, royalty arrangement, or authorised-generic deal as part of the settlement.
Filing to Dismissed without Prejudice in 306 days
306 days — resolved below the median ANDA Hatch-Waxman district court lifecycle
Consent injunction entered: what the stipulated order means for both parties
ANDA filing treated as infringement under § 271(e)(2)(A)
Under the Hatch-Waxman Act, the submission of an ANDA containing a Paragraph IV certification constitutes a technical act of patent infringement under 35 U.S.C. § 271(e)(2)(A). MSN stipulated that ANDA No. 213576 infringed both asserted patents, allowing the court to enter an infringement finding and injunction without a full trial. Remaining claims were dismissed without prejudice — meaning they are not extinguished and could be re-litigated if facts change.
Stipulated infringement findingPermanent injunction secures Viberzi® market exclusivity through patent expiry
The stipulated order bars MSN from commercialising its generic eluxadoline product in the US for the full remaining life of the ‘527 and ‘187 Patents, including any extensions and paediatric exclusivities. For AbbVie and Allergan, this preserves Viberzi® revenue without the cost and risk of trial. The without-prejudice carve-out for non-ANDA-213576 products is a standard protection ensuring the injunction does not sweep beyond the specific generic application at issue.
Exclusivity preservedMSN’s US eluxadoline launch blocked — appeal rights expressly waived
MSN expressly waived any right to appeal or seek relief from the stipulated order, creating a final, binding bar to US launch of the ANDA No. 213576 products. This is a commercially significant concession. However, the without-prejudice framing of dismissed claims means MSN retains the theoretical ability to challenge the patents in a future action tied to a different product or formulation — a narrow but not insignificant reservation.
Appeal rights waivedViberzi IP wall reinforced — other ANDA filers should note the injunction scope
The consent injunction explicitly extends to all persons in active concert with MSN, making it a practically enforceable market-exclusion order. Other generic manufacturers pursuing eluxadoline ANDAs should treat both the ‘527 and ‘187 Patents as actively enforced barriers. The resolution without trial means neither patent received full judicial validity scrutiny, which may encourage future challengers to press invalidity arguments rather than settling. Patent-term extensions and paediatric exclusivity provisions could extend exclusivity materially beyond base expiry.
Active enforcement postureFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Allergan Holdings Unlimited Co. | Company | AbbVie/Allergan — branded pharmaceutical group, holder of Viberzi® eluxadoline patentsSearch in Eureka ↗ |
| Co-Plaintiff | AbbVie US LLC | Company | Search in Eureka ↗ |
| Co-Plaintiff | Eden Biodesign, LLC | Company | Search in Eureka ↗ |
| Co-Plaintiff | AbbVie, Inc. | Company | Search in Eureka ↗ |
| Defendant | MSN Laboratories Private Limited | Individual | MSN Laboratories — Indian generic pharmaceutical manufacturer, ANDA filer for generic eluxadolineSearch in Eureka ↗ |
| Co-Defendant | MSN Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Allergan Holdings Unlimited Co.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Allergan Holdings Unlimited Co.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Allergan Holdings Unlimited Co.Search in Eureka ↗ |
| Defendant counsel | Richard C. Weinblatt | Attorney | Counsel for MSN Laboratories Private LimitedSearch in Eureka ↗ |
| Defendant law firm | Stamoulis & Weinblatt LLC | Law Firm | Representing MSN Laboratories Private LimitedSearch in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated order combines a binding infringement finding under § 271(e)(2)(A) with a permanent injunction and an express appeal waiver — an unusually complete resolution for a pre-trial ANDA case. The without-prejudice dismissal of remaining claims is procedurally significant: it does not constitute a merits adjudication of validity or other defences, meaning those issues survive for potential future litigation. MSN’s waiver of appellate rights removes any near-term challenge path to this specific injunction.
US12097187B2 — Eluxadoline oral tablet formulation for IBS-D
US12097187B2 (application no. US18/324449) covers eluxadoline oral tablet formulations — a mu-opioid receptor agonist and delta-opioid receptor antagonist indicated for irritable bowel syndrome with diarrhoea (IBS-D). The patent is one of two patents asserted in this action (alongside the ‘527 Patent), collectively forming the IP barrier protecting Allergan’s Viberzi® brand. The application number suggests a relatively recent continuation or divisional filing, consistent with lifecycle management strategies common in branded pharmaceutical portfolios.
Eluxadoline represents a distinct mechanistic class within the IBS-D space, and the asserted patents cover the specific formulated tablet products rather than the bare active ingredient. This formulation-level protection is strategically valuable because it narrows the design-around space available to generic challengers. Any generic manufacturer targeting the eluxadoline market must contend with both the ‘527 and ‘187 Patents, and the consent injunction entered against MSN signals that at least one major ANDA filer did not find a viable non-infringing path at the 75 mg and 100 mg dose strengths.
Should your R&D or regulatory team run an FTO against US12097187B2?
Any pharmaceutical company, CDMO, or generic manufacturer developing eluxadoline oral solid dosage forms — whether at 75 mg, 100 mg, or alternative strengths — should treat US12097187B2 and the co-asserted ‘527 Patent as active freedom-to-operate obstacles. The consent injunction entered against MSN confirms that AbbVie and Allergan are actively enforcing these patents in Delaware. Even if your formulation differs from ANDA 213576, the without-prejudice dismissal language signals that plaintiffs may pursue future infringers through separate actions.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US12097187B2 against your specific formulation parameters, identify prior art that survived or was not tested in the MSN action, and flag co-pending continuation applications that may extend the patent family’s reach. For regulatory teams, Eureka’s patent-to-product mapping can also identify any paediatric exclusivity filings that could extend the effective exclusivity window beyond the base patent expiry date.
Run a freedom-to-operate analysis on US12097187B2 to assess your product’s exposure
Run FTO in Eureka →Related ANDA & Hatch-Waxman patent cases involving gastrointestinal drug formulations
Cases involving ANDA Paragraph IV challenges to gastrointestinal drug formulation patents in the District of Delaware, with comparable consent injunction or stipulated order resolutions.
What this case signals for the Hatch-Waxman gastrointestinal drug IP landscape
AbbVie’s clean consent win over MSN reinforces a broader pattern of branded pharma securing early stipulated injunctions in Delaware ANDA cases.
Early stipulated orders are becoming a preferred Hatch-Waxman endgame
MSN’s decision to concede infringement and waive appeal rights — rather than mount a validity challenge — is consistent with a broader industry trend where generic filers without strong invalidity positions settle quickly. Branded pharma IP teams should treat Delaware consent injunctions as a reliable enforcement mechanism, particularly where the ANDA filer lacks a non-infringement design-around.
Without-prejudice carve-outs preserve future challenge windows for generics
The order explicitly preserves MSN’s right to bring future actions regarding the same patents tied to a product other than ANDA 213576. Generic manufacturers and their IP counsel should recognise this as a strategic reservation: a reformulated product or different dosage form could re-open patent validity disputes. Branded IP teams should monitor downstream ANDA filings from MSN closely.
Allergan v MSN — key questions answered
Two patents were asserted: US12097187B2 (the ‘187 Patent, covering eluxadoline oral tablet formulations) and a second patent referred to in the order as the ‘527 Patent. Both were enforced against MSN’s ANDA No. 213576 for generic eluxadoline tablets at 75 mg and 100 mg strengths under 35 U.S.C. § 271(e)(2)(A).
The court entered a stipulated order finding that ANDA No. 213576 infringed both asserted patents and permanently enjoining MSN from manufacturing, using, selling, or importing the generic eluxadoline products in the United States for the life of the patents, including any extensions and paediatric exclusivities, absent a licence. MSN expressly waived all appeal rights.
The without-prejudice dismissal of remaining claims technically preserves MSN’s right to bring a future action regarding the ‘527 and ‘187 Patents if the product at issue differs from the ANDA 213576 generic eluxadoline tablets. However, the infringement finding and injunction as to ANDA 213576 are binding and final, with appeal rights waived.
The case was filed on 23 October 2024 and closed on 25 August 2025 — a duration of 306 days. This is relatively swift for a Hatch-Waxman ANDA case in Delaware, suggesting the parties reached the stipulated resolution well before any scheduled trial date, consistent with MSN not pursuing a validity defence.
The injunction covers the generic eluxadoline oral tablet products at 75 mg and 100 mg strengths described by ANDA No. 213576, which are the bioequivalent generic versions of Allergan’s branded Viberzi® product indicated for irritable bowel syndrome with diarrhoea (IBS-D). The injunction does not extend to other eluxadoline products outside that specific ANDA.
PatSnap Eureka searches patents and litigation data to answer instantly.